MCRB News and Press, Seres Therapeutics Inc. From 04/18/23

2023-04-18 08:33:45 ET BELLUS Health  ( BLU ) +98% surges ~100% after GSK reaches deal to acquire cough drugmaker for ~$2B . Dermata Therapeutics ( DRMA ) +92% . Gamida Cell  ( GMDA ) +42% . Femasys  ( FEMY ) +31% femaSeed local...

2023-04-17 13:30:07 ET Seres Therapeutics ( NASDAQ: MCRB ) shares added ~11% on Monday to reach the highest level since December as the microbiome therapeutics company awaits the FDA decision on its biologics license application for lead candidate SER-109. Evogene ( EVGN ...

2023-04-05 15:43:51 ET Summary Due to its volatility, Seres Therapeutics, Inc. is a stock that is not for the faint of heart. Seres Therapeutics stock dropped and popped substantially from the outcome of its previous clinical catalysts. The upcoming SER109 approval can substan...

2023-03-23 17:01:12 ET Gainers: Pyxis Oncology ( PYXS ) +15% . CRISPR Therapeutics ( CRSP ) +11% . ADMA Biologics ( ADMA ) +6% . Harrow Health ( HROW ) +4% . Solid Power ( SLDP ) +5% . Losers: Scholastic ( SCHL ) -1...

2023-03-21 10:03:51 ET Gainers: ImmunityBio ( IBRX ) +21% . NuCana ( NCNA ) +16% . Seres Therapeutics ( MCRB ) +14% . SCYNEXIS ( SCYX ) +13% . Corbus Pharmaceuticals ( CRBP ) +12% . Losers: Altimmune ( ALT ) ...

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will provide a corporate presentation at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday, March 15, 20...

2023-03-07 14:05:12 ET Seres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Conference Call March 07, 2023, 08:30 ET Company Participants Carlo Tanzi - IR Officer Eric Shaff - President, CEO & Director Teresa Young - EVP and Chief Commercial & Strategy Office...

2023-03-07 12:20:01 ET Seres Therapeutics ( NASDAQ: MCRB ) is trading ~9% lower premarket after the company missed revenue and GAAP EPS estimates, as costs rose. Seres Therapeutics FY GAAP EPS of -$2.31 missed by $0.15, while revenue fell 95.5% to $7.13M, and missed estima...

2023-03-07 07:01:08 ET Seres Therapeutics press release ( NASDAQ: MCRB ): FY GAAP EPS of -$2.31 misses by $0.15 . Revenue of $7.13M (-95.1% Y/Y) misses by $6.62M . For further details see: Seres Therapeutics GAAP EPS of -$2.31 misses by $0.15, revenue of ...

– SER-109 Biologics License Application (BLA) under review with U.S. Food and Drug Administration (FDA) with target action date of April 26, 2023 under Prescription Drug User Fee Act (PDUFA) – – Anticipate SER-109 commercial launch soon after potential FDA approva...